374 related articles for article (PubMed ID: 28522744)
21. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of metabolic response measured by 18F-FDG-PET in oesophageal cancer patients treated with definitive chemoradiotherapy.
Onal C; Torun N; Guler OC; Yildirim BA
Nucl Med Commun; 2016 Dec; 37(12):1282-1289. PubMed ID: 27612030
[TBL] [Abstract][Full Text] [Related]
23. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation.
Suzuki A; Xiao L; Taketa T; Sudo K; Wadhwa R; Blum MA; Skinner H; Komaki R; Weston B; Lee JH; Bhutani MS; Rice DC; Maru DM; Erasmus J; Swisher SG; Hofstetter WL; Ajani JA
Ann Oncol; 2013 Nov; 24(11):2854-9. PubMed ID: 23994746
[TBL] [Abstract][Full Text] [Related]
24. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
[TBL] [Abstract][Full Text] [Related]
25. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW
BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914
[TBL] [Abstract][Full Text] [Related]
26. Positron-Emission Tomography Scan-Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders.
Greally M; Chou JF; Molena D; Rusch VW; Bains MS; Park BJ; Wu AJ; Goodman KA; Kelsen DP; Janjigian YY; Ilson DH; Ku GY
J Thorac Oncol; 2019 Mar; 14(3):540-546. PubMed ID: 30391577
[TBL] [Abstract][Full Text] [Related]
27. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
Levine EA; Farmer MR; Clark P; Mishra G; Ho C; Geisinger KR; Melin SA; Lovato J; Oaks T; Blackstock AW
Ann Surg; 2006 Apr; 243(4):472-8. PubMed ID: 16552197
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients.
Kim SJ; Koo PJ; Chang S
Cancer Chemother Pharmacol; 2016 Apr; 77(4):723-31. PubMed ID: 26891957
[TBL] [Abstract][Full Text] [Related]
29. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Hölscher AH; Dietlein M; Bollschweiler E; Baldus SE; Mönig SP; Metzger R; Schicha H; Schmidt M
Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
[TBL] [Abstract][Full Text] [Related]
30. Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
Yap WK; Chang YC; Hsieh CH; Chao YK; Chen CC; Shih MC; Hung TM
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):689-698. PubMed ID: 29188300
[TBL] [Abstract][Full Text] [Related]
31. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma.
Hong D; Lunagomez S; Kim EE; Lee JH; Bresalier RS; Swisher SG; Wu TT; Morris J; Liao Z; Komaki R; Ajani JA
Cancer; 2005 Oct; 104(8):1620-6. PubMed ID: 16118804
[TBL] [Abstract][Full Text] [Related]
32. Intratumor Textural Heterogeneity on Pretreatment (18)F-FDG PET Images Predicts Response and Survival After Chemoradiotherapy for Hypopharyngeal Cancer.
Oh JS; Kang BC; Roh JL; Kim JS; Cho KJ; Lee SW; Kim SB; Choi SH; Nam SY; Kim SY
Ann Surg Oncol; 2015 Aug; 22(8):2746-54. PubMed ID: 25487968
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of ¹⁸F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis.
Leibold T; Akhurst TJ; Chessin DB; Yeung HW; Macapinlac H; Shia J; Minsky BD; Saltz LB; Riedel E; Mazumdar M; Paty PB; Weiser MR; Wong WD; Larson SM; Guillem JG
Ann Surg Oncol; 2011 Oct; 18(10):2783-9. PubMed ID: 21476107
[TBL] [Abstract][Full Text] [Related]
34. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment.
Wieder HA; Brücher BL; Zimmermann F; Becker K; Lordick F; Beer A; Schwaiger M; Fink U; Siewert JR; Stein HJ; Weber WA
J Clin Oncol; 2004 Mar; 22(5):900-8. PubMed ID: 14990646
[TBL] [Abstract][Full Text] [Related]
35. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
36. The Role of 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography/Computed Tomography as Response and Prognosis Predictive Factor of Concurrent Chemoradiotherapy after Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Study.
Šedienė S; Kulakienė I; Rudžianskas V; Ambrazienė R
Medicina (Kaunas); 2018 May; 54(2):. PubMed ID: 30344262
[No Abstract] [Full Text] [Related]
37. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
Lordick F; Ott K; Krause BJ; Weber WA; Becker K; Stein HJ; Lorenzen S; Schuster T; Wieder H; Herrmann K; Bredenkamp R; Höfler H; Fink U; Peschel C; Schwaiger M; Siewert JR
Lancet Oncol; 2007 Sep; 8(9):797-805. PubMed ID: 17693134
[TBL] [Abstract][Full Text] [Related]
38. To evaluate the treatment response of locally advanced esophageal cancer after preoperative chemoradiotherapy by FDG-PET/CT scan.
Huang JW; Yeh HL; Hsu CP; Lu YY; Chuang CY; Lin JC; Lin JF; Chang CF
J Chin Med Assoc; 2015 Apr; 78(4):229-34. PubMed ID: 25557468
[TBL] [Abstract][Full Text] [Related]
39. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial.
zum Büschenfelde CM; Herrmann K; Schuster T; Geinitz H; Langer R; Becker K; Ott K; Ebert M; Zimmermann F; Friess H; Schwaiger M; Peschel C; Lordick F; Krause BJ
J Nucl Med; 2011 Aug; 52(8):1189-96. PubMed ID: 21764790
[TBL] [Abstract][Full Text] [Related]
40. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using
Borggreve AS; Goense L; van Rossum PSN; Heethuis SE; van Hillegersberg R; Lagendijk JJW; Lam MGEH; van Lier ALHMW; Mook S; Ruurda JP; van Vulpen M; Voncken FEM; Aleman BMP; Bartels-Rutten A; Ma J; Fang P; Musall BC; Lin SH; Meijer GJ
Int J Radiat Oncol Biol Phys; 2020 Apr; 106(5):998-1009. PubMed ID: 31987972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
